From: Human iPSC-derived glia models for the study of neuroinflammation
Stimulus | Stimulus concentration | Stimulus time | Method | Measure of inflammation | References |
---|---|---|---|---|---|
TNF | 10Â ng/mL | 24Â h | RT-qPCR | Increased IL8, IL1B, IFNG, TNF, IL2, IL4, IL6, IL10 | [88] |
Cytometric bead array | Increased IL-8, IL-1β, IFN-γ, TNF, IL-2, IL-4, IL-6, IL-10 | [91] | |||
48Â h | Cytometric bead array | Increased IL-8 | [91] | ||
5Â days | Bulk RNA sequencing | Increased IL6, C3, CXCL10, CXCL11 amongst others | [92] | ||
Immunostaining | Increased GFAP intensity | [88] | |||
Multiplex bead-based immunoassays | Increased GM-CSF, IL-1β | [94] | |||
30 ng/mL | 7 days | Western Blot | Increased NF-κB phosphorylation | [90] | |
50 ng/mL | 1.5 h | Immunostaining | Increased NF-κB nuclear translocation | [88] | |
5Â h | Flow cytometry | Increased IL-8 and IL-6 | [89] | ||
24Â h | Cytometric bead array | Increased IL-8 | [91] | ||
48Â h | Cytometric bead array | Increased IL-8 | [91] | ||
48Â h | RT-qPCR | Increased CCL5, CXCL8 | [93] | ||
7Â days | Western blot | No change in GFAP expression | [93] | ||
ELISA | Increased IL-6 | [93] | |||
100Â ng/mL | 7Â days | Bulk RNA sequencing | Increased IL8, C3, CXCL10 and CXCL11 amongst others | [90] | |
Western Blot | Increased NF-κB phosphorylation | [90] | |||
IL-1β | 10 ng/mL | 5 h | Bulk RNA sequencing | Enrichment for inflammation-related GO terms | [89] |
5Â h | Flow cytometry | Increased IL-6 and IL-8 | [89] | ||
24Â h | Cytometric bead array | Increased IL-8 | [91] | ||
48Â h | Cytometric bead array | Increased IL-8 | [91] | ||
48Â h | RT-qPCR | Increased CCL5, CXCL8 | [93] | ||
5 days | Multiplex bead-based immunoassays | Increased IL-6, GM-CSF, TNF, IL-23, IFN-β, IFN-α | [94] | ||
7Â days | Western Blot | Increased GFAP expression | [93] | ||
ELISA | Increased IL-6 | [93] | |||
100Â ng/mL | 7Â days | Bulk RNA sequencing | Increased IL8, C3, CXCL10 and CXCL11 amongst others | [90] | |
Western Blot | No change in NF-κB phosphorylation | [90] | |||
TNF and IL-1β | 10 ng/mL TNF and 10 ng/mL IL-1β | 1 h | RT-qPCR | Decreased GFAP | [96] |
Western blot | Decreased GFAP | [96] | |||
Immunostaining | Increased NF-κB nuclear translocation | [96] | |||
5 days | Multiplex bead-based immunoassays | Increased GM-CSF, TNF, IL-1α, IL-6, IL-10, IL-12, IL-23, IFN-β, IFN-α | [94] | ||
7Â days | RT-qPCR | Increased CCL5, CXCL8, C3, LCN2 | [96] | ||
ELISA | Increased IL-6 | [96] | |||
24Â h | Multiplex bead-based immunoassays | Increased C3a, MCP-3, I-TAC, GRO-a, sICAM-1, GM-CSF, IL-1RA, MIG, RANTES, IL-6, MCP-2, MIP-1a | [98] | ||
IL-1α, TNF, and C1q | 3 ng/mL IL-1α, 30 ng/mL TNF, and 400 ng/mL C1q | 24 h | Multiplex bead-based immunoassays | Increased C3a, MCP-3, I-TAC, GRO-a, sICAM-1, GM-CSF, MIG, RANTES, IL-6, MCP-2, MIP-1a | [98] |
Western blot | No change in GFAP | [98] | |||
RT-qPCR | Increased TNF and IL-1β, decreased GFAP | [97] | |||
Whole proteome analysis | Enrichment of GO-terms related to immune responses, cytokine-associated signalling, and recruitment of peripheral immune cells following treatment | [147] | |||
Amyloid-beta fibrils (Aβ-F) | 0.2 µM | 24 h | Cytokine array | Measured 36 human chemokines and cytokines, no change detected | [79] |
α-Synuclein fibrils (αSYN-F) | 0.5 µM | 24 h | Cytokine array | Measured 36 human chemokines and cytokines, no change detected | [79] |